Compare Amphastar Pharmaceuticals Inc (AMPH) vs Paycom Software Inc (PAYC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Paycom Software Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Paycom Software Inc trades at $140.1 (market cap $6.48B). The key difference: Paycom Software Inc is far larger — about 7.8× Amphastar Pharmaceuticals Inc's market cap, and Paycom Software Inc pays a 1.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PAYC | |
|---|---|---|
Market Cap | $826.08M | $6.48B |
Sector | Health | Technology |
52-Week High | $30.81 | $238.80 |
52-Week Low | $16.87 | $113.59 |
Enterprise Value | $1.22B | $7.09B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Paycom Software (PAYC) trades at $139.08, down 0.34% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 22.44% net income margin and 37.15% ROE, though recent Q3 2025 EPS slightly missed expectations. Recent board appointments and industry awards highlight ongoing corporate development. The consensus price target is $151.00, suggesting potential upside from current levels.
The outlook remains balanced with solid fundamentals supporting growth, but risks include competitive pressures and execution challenges. Analyst sentiment is mixed with near-equal buy and hold ratings. Revenue growth stability and margin maintenance are key for sustained investor confidence amid a neutral oscillator signal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
